June 28, 2019 / 10:50 AM / 4 months ago

BRIEF-Roche Reports EMA Committee Recommendation TO Approve Atezolizumab

June 28 (Reuters) - Roche Holding AG:

* EUROPEAN MEDICINES AGENCY’S (EMA) COMMITTEE HAS RECOMMENDED APPROVAL OF TECENTRIQ (ATEZOLIZUMAB) PLUS CHEMOTHERAPY (ABRAXANE®; NAB-PACLITAXEL) FOR SPECIFIC GROUP OF PATIENTS

* EUROPEAN MEDICINES AGENCY’S (EMA) COMMITTEE RECOMMENDATION BASED ON THE RESULTS OF IMPASSION130 STUDY IN TRIPLE-NEGATIVE BREAST CANCER Source text: [bit.ly/2RItKSl] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below